Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Oryzon Genomics — 4 videos in collection

More on this equity

Spanish biotech Oryzon Genomics is among the leading clinical-stage drug developers, with a second generation of epigenetic therapeutics that have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors. Oryzon is focused on epigenetics in oncology and the central nervous system (CNS). Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. CNS asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder is now the lead study.

In this interview, Oryzon CEO Carlos Buesa recaps the company’s pipeline and provides a preview of the upcoming rich newsflow.

You may also be interested in these:


Oryzon– Edison Open House interview


Executive interview – Oryzon

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free